Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 2,64 M
EBIT 2016 -58,2 M
Net income 2016 -58,4 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,47 M
EBIT 2017 -63,9 M
Net income 2017 -63,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 50,1x
Capi. / Sales2017 279x
Capitalization 132 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
09/25 ANTHERA PHARMACEUTICALS : Announces Initial $17.0 Million Closing of a Potential..
09/20 ANTHERA PHARMACEUTICALS : Research Reports Initiation on Biotech Stocks -- Agenu..
09/15 ANTHERA PHARMACEUTICALS INC : Amendments to Articles of Inc. or Bylaws; Change i..
09/12 ANTHERA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Amendm..
09/08 Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potentia..
08/17 ANTHERA PHARMACEUTICALS : Announces Positive DSMB Review in Phase 3 SOLUTION Stu..
08/16 ANTHERA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
08/16 Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as ..
08/16 Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION St..
08/09 ANTHERA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
More news
Sector news : Bio Therapeutic Drugs
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 206%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paul F. Truex Chief Executive Officer & Director
John Craig Thompson President & Chief Operating Officer
Christopher S. Henney Chairman
May Liu CAO, Senior VP-Finance & Administration
Chuck Olson Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR132
AMGEN, INC.7.68%130 813
GILEAD SCIENCES, INC.-19.59%107 381
CELGENE CORPORATION-8.63%84 821
REGENERON PHARMACEUTIC..-24.40%43 212
VERTEX PHARMACEUTICALS..-27.97%22 456
More Results